Takeda ADS holder plans sale of 24,887 shares

Takeda Pharmaceutical Company Limited filed a notice for the proposed sale of 24,887 American Depositary Shares (ADSs) through Interactive Brokers LLC on or about July 13, 2026 on the NYSE, with an aggregate market value of $416,850.49.

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited filed a notice for the proposed sale of 24,887 American Depositary Shares (ADSs) through Interactive Brokers LLC on or about July 13, 2026 on the NYSE, with an aggregate market value of $416,850.49. The filing lists 143,310,556 ADSs outstanding as context. It also notes prior transactions over the past three months, including 56,486 ADSs related to Restricted Stock Unit Awards – Vested dated July 1, 2026 and categorized as compensation.

Filing Explained

The July 13 filing proposes an ADS sale, but does not establish that the transfer has occurred.

The July 13 Form 144 reports a proposed sale of ADSs, so the disclosed event is a contemplated holder transfer rather than a completed sale or an issuance by Takeda.

The ADSs are listed as acquired on July 1, 2026 through vested restricted stock unit awards, with compensation shown as the payment type.

The securities information lists ADSs and 143,310,556 as the associated aggregate market value, with July 13, 2026 shown as the sale date.

The filing contains no trading-plan disclosure, so this is a sale with no trading plan disclosed in this filing.

The key filing-specific watch item is completion: the July 13 Form 144 does not establish that the ADSs were sold.

Key Figures

ADSs to be sold: 24,887 ADSs Aggregate market value: $416,850.49 ADSs outstanding: 143,310,556 ADSs +3 more

6 metrics

ADSs to be sold 24,887 ADSs Proposed sale through Interactive Brokers LLC on or about July 13, 2026

Aggregate market value $416,850.49 Value of the 24,887 ADSs proposed to be sold

ADSs outstanding 143,310,556 ADSs Shares outstanding for Takeda Pharmaceutical Company Limited

ADSs sold in past 3 months 56,486 ADSs Related to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation

Approximate sale date 07/13/2026 Planned trading date for the proposed ADS sale on NYSE

RSU vesting date 07/01/2026 Date of Restricted Stock Unit Awards – Vested referenced in past 3-months transactions

Key Terms

American Depositary Shares (ADSs), Restricted Stock Unit Awards - Vested, compensation

3 terms

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards - Vested financial

"ADSs | 07/01/2026 | Restricted Stock Unit Awards - Vested."

compensation financial

"56486 | 07/01/2026 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Takeda (TAK) disclose in this Form 144 filing?

Takeda discloses a proposed sale of 24,887 ADSs with an aggregate market value of $416,850.49, to be executed through Interactive Brokers LLC on or about July 13, 2026 on the NYSE.

How many Takeda (TAK) ADSs are proposed to be sold and through which broker?

The filing lists a proposed sale of 24,887 ADSs of Takeda Pharmaceutical Company Limited to be handled by Interactive Brokers LLC and traded on the NYSE around July 13, 2026.

What is the aggregate market value of the Takeda (TAK) ADSs covered by this notice?

The aggregate market value of the ADSs covered by the notice is $416,850.49. This value corresponds to the proposed sale of 24,887 ADSs to be traded on or about July 13, 2026.

How many Takeda (TAK) ADSs are reported as outstanding in the filing?

The filing reports 143,310,556 ADSs outstanding. This figure provides context for the company’s total ADS float and is separate from the 24,887 ADSs proposed to be sold under this notice.

What past 3‑month transactions are disclosed for Takeda (TAK) ADSs?

The filing notes past three‑month activity of 56,486 ADSs tied to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation related to Takeda Pharmaceutical Company Limited.

What is the source of the Takeda (TAK) ADSs mentioned in the past sales section?

In the past three months, 56,486 ADSs are linked to Restricted Stock Unit Awards – Vested on July 1, 2026. These ADSs are categorized as compensation associated with Takeda Pharmaceutical Company Limited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 06:26 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977817
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo JAPAN 103-8668
Phone	81-3-3278-2111
Name of Person for Whose Account the Securities are To Be Sold	Marcello Pignagnoli Agosti
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Interim Head, Strategy and Portfolio Development

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	24887	416850.49	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			56486	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	07/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kate Huleatt, by power of attorney, for Marcello Agosti
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)